What is the efficacy of early initiation of HIV post‑exposure prophylaxis (PEP) and pre‑exposure prophylaxis (PrEP) in preventing HIV infection?

Early HIV Prophylaxis: Initiate PEP Within 72 Hours and Consider PrEP for Ongoing Risk

Early initiation of HIV post-exposure prophylaxis (PEP) within 72 hours of exposure is highly effective (>90% efficacy when started within 48 hours), and pre-exposure prophylaxis (PrEP) provides 86-92% protection with adherence—both are critical interventions that must be deployed rapidly to prevent HIV acquisition 1, 2.

Post-Exposure Prophylaxis (PEP): Timing is Everything

Critical Initiation Window

The efficacy of PEP is fundamentally dependent on how quickly you start treatment after exposure:

• Within 48 hours: Three-drug PEP regimens achieve >90% efficacy when taken for 14-28 days 2
• Within 72 hours: This is the absolute outer limit for PEP initiation—efficacy drops substantially beyond this window 1, 2
• After 72 hours: PEP is generally not recommended as efficacy becomes unreliable

The biological rationale is clear: early intervention prevents viral establishment before HIV can integrate into host cells. Meta-analysis of nonhuman primate studies confirms 89% lower seroconversion risk with PEP versus no treatment, with timing being the most significant predictor of success 3.

Optimal PEP Regimen

Use a 3-drug regimen for 28 days 1, 2. While two-drug regimens (TDF/FTC alone) may be insufficient when initiated >1 hour post-exposure, adding a third drug extends the protective window 2. The 2025 CDC guidelines now recommend coformulated antiretrovirals as preferred regimens, which improves adherence 4.

PEP-to-PrEP Transition

Seamlessly transition from PEP to PrEP after completing the 28-day course if ongoing HIV risk continues 1. This is critical because the exposure event that prompted PEP often signals ongoing risk. Confirm negative HIV testing (ideally antigen/antibody plus RNA assay) at PEP completion before starting PrEP 1.

Pre-Exposure Prophylaxis (PrEP): Highly Effective Prevention

Efficacy Data

PrEP efficacy varies by adherence but is remarkably effective when taken correctly:

• Daily oral TDF/FTC: 49-86% efficacy in intention-to-treat analyses, but 92-99% efficacy with confirmed adherence 5
• Long-acting injectable cabotegravir: Superior to daily oral PrEP with up to 89% relative risk reduction 1, 5
• On-demand dosing (2-1-1): Effective for cisgender men having receptive anal sex—double dose 2-24 hours before sex, then single doses at 24 and 48 hours after the first dose 1

Rapid PrEP Start

Do not delay PrEP initiation—any delay is a missed prevention opportunity 1. If you have negative HIV serology from within 7 days or a negative rapid test on the day of initiation, start PrEP immediately while awaiting additional diagnostics 1. This "rapid start" approach prioritizes prevention over administrative convenience.

Regimen Selection Algorithm

For cisgender men and transgender women (no receptive vaginal sex):

• Daily TDF/FTC or TAF/FTC (TAF preferred if creatinine clearance 30-60 mL/min or osteopenia/osteoporosis) 1
• On-demand 2-1-1 dosing with TDF/FTC (take with food if on gender-affirming hormones) 1
• Long-acting cabotegravir injections every 2 months 1

For cisgender women or anyone with receptive vaginal/neovaginal exposure:

• Daily TDF/FTC only (TAF/FTC and on-demand dosing lack efficacy data for vaginal exposures) 1
• Long-acting cabotegravir 1

For people who inject drugs:

• Daily TDF/FTC (insufficient data for TAF/FTC or on-demand dosing) 1
• Long-acting cabotegravir if also at risk through sexual exposures 1

Long-Acting Cabotegravir Specifics

The oral lead-in is optional but recommended for those with severe atopic histories 1. Importantly, do not use an oral lead-in for patients who struggle with daily pill adherence—this defeats the purpose of choosing an injectable 1. Overlap the first injection with 7 days of oral PrEP (either cabotegravir tablets or TDF/FTC) to ensure immediate protection 1.

Synergy Between PrEP and PEP

Recent PrEP use enhances subsequent PEP efficacy by delaying initial viral dynamics and maintaining protective drug concentrations 2. This means patients on PrEP who experience a high-risk exposure can self-start additional TDF/FTC immediately while seeking medical evaluation for a third drug, rather than waiting for an appointment 2. This "PrEP-to-PEP transition" is more effective than no immediate action.

Common Pitfalls to Avoid

1. Delaying PEP beyond 72 hours: The window closes rapidly—counsel patients to seek care immediately after any high-risk exposure
2. Using 2-drug PEP alone: Always use a 3-drug regimen for PEP 2
3. Stopping at PEP completion without assessing ongoing risk: Most patients who need PEP also need PrEP 1, 6
4. Requiring bone density scans before starting PrEP: These are not necessary 1
5. Risk-based screening only: This misses many eligible patients—consider annual screening for all sexually active patients 7
6. Forgetting food with 2-1-1 dosing in transgender women: This significantly impacts drug levels 1